Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2025-12-25 @ 2:17 AM
NCT ID:
NCT06311760
Brief Summary:
This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants.
Detailed Description:
This is a First-time-in-human (FTiH) trial.
Eligible participants will be randomized to receive AZD0292 or Placebo. Participants will receive pre-medication with an antihistamine prior to dosing with the study intervention.
The study will comprise:
1. A Screening Period of maximum 28 days.
2. A Treatment Period
3. A Follow-up Period from Day 3 to Day 16
4. An extended Follow-up Period from Day 17 to Day 61
Participants will be involved in this study for a maximum duration of 13 weeks.
Study:
NCT06311760
Study Brief:
Protocol Section:
NCT06311760